Evogene (EVGN) Beginning Cash Balance (2013 - 2025)
Evogene (EVGN) posted Beginning Cash Balance of $5.6 million for Q4 2025, down 32.45% sequentially from $8.3 million in Q3 2025, and down 50.29% YoY from $11.3 million in Q4 2024.
Evogene (EVGN) Beginning Cash Balance (2013 - 2025) Analysis & Trends
Evogene has reported Beginning Cash Balance for 13 years, with the latest figure at $5.6 million in Q4 2025.
- Quarterly Beginning Cash Balance fell 50.29% year-over-year to $5.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $32.8 million (down 45.43% YoY) and the FY2025 annual result came in at $15.3 million, down 26.34% from the prior year.
- Beginning Cash Balance fell to $5.6 million in Q4 2025 per EVGN's latest filing, from $8.3 million in the prior quarter.
- Over five years, Beginning Cash Balance peaked at $46.2 million in Q1 2021 and troughed at $5.6 million in Q4 2025.
- A 5-year average of $23.7 million and a median of $23.0 million in 2023 frame the typical range for Beginning Cash Balance.
- The sharpest annual moves came in 2021 and 2024: Beginning Cash Balance surged 37.59% in 2021, then plunged 58.59% in 2024.
- Over 5 years, Beginning Cash Balance stood at $37.6 million in 2021, then declined by 23.29% to $28.9 million in 2022, then decreased by 5.32% to $27.3 million in 2023, then slumped by 58.59% to $11.3 million in 2024, then plunged by 50.29% to $5.6 million in 2025.
- According to Business Quant data, Beginning Cash Balance over the past three periods registered $5.6 million, $8.3 million, and $7.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.63 Mn |
| Dec 31, 2025 | 5.63 Mn |
| Sep 30, 2025 | 8.33 Mn |
| Sep 30, 2025 | 8.33 Mn |
| Jun 30, 2025 | 7.50 Mn |
| Jun 30, 2025 | 7.50 Mn |
| Dec 31, 2024 | 11.32 Mn |
| Dec 31, 2024 | 11.32 Mn |
| Sep 30, 2024 | 9.48 Mn |
| Sep 30, 2024 | 9.48 Mn |
| Jun 30, 2024 | 11.92 Mn |
| Jun 30, 2024 | 11.92 Mn |
| Dec 31, 2023 | 27.33 Mn |
| Dec 31, 2023 | 27.33 Mn |
| Sep 30, 2023 | 20.23 Mn |
| Sep 30, 2023 | 20.23 Mn |
| Jun 30, 2023 | 23.00 Mn |
| Jun 30, 2023 | 23.00 Mn |
| Sep 30, 2022 | 28.87 Mn |
| Sep 30, 2022 | 28.87 Mn |